SCHEMBL9923019

SCHEMBL9923019

CNc1ccc2c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(C)s4)cc3)c(=O)[nH]c2c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY12 Q9H244 1/20 0.65
TP53 P04637 2/20 0.39
MAPT P10636 1/20 0.39
ERCC1 P07992 1/20 0.39
FEN1 P39748 1/20 0.39
ERCC4 Q92889 1/20 0.39
RXFP1 Q9HBX9 3/20 0.37
KMT2A Q03164 4/20 0.36
ALDH1A1 P00352 3/20 0.36
LMNA P02545 3/20 0.36
HPGD P15428 2/20 0.36
KDM4E B2RXH2 1/20 0.36
PPARG P37231 1/20 0.35
GAA P10253 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
NPC1 O15118 1/20 0.35
BRD4 O60885 1/20 0.35
CREBBP Q92793 1/20 0.35
HSD17B10 Q99714 2/20 0.35
USP2 O75604 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9922487 0.91 P2RY12 (0.78) P2RY12TP53MAPTERCC1FEN1
SCHEMBL12177205 0.90 P2RY12 (0.58) P2RY12TP53MAPTERCC1FEN1
SCHEMBL13638630 0.89 P2RY12 (0.56) P2RY12TP53MAPTERCC1FEN1
SCHEMBL12177347 0.89 P2RY12 (0.54) P2RY12ERCC1FEN1ERCC4KMT2A
SCHEMBL12177250 0.88 P2RY12 (0.58) P2RY12TP53MAPTRXFP1KMT2A
SCHEMBL682018 0.88 P2RY12 (0.84) P2RY12TP53MAPTRXFP1KMT2A
SCHEMBL12177355 0.88 P2RY12 (0.57) P2RY12TP53MAPTERCC1FEN1
SCHEMBL12177432 0.87 P2RY12 (0.58) P2RY12TP53MAPTERCC1FEN1
SCHEMBL9922446 0.87 P2RY12 (0.53) P2RY12TP53ERCC1FEN1ERCC4
SCHEMBL14113679 0.87 P2RY12 (0.56) P2RY12TP53MAPTERCC1FEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS TBXA2R, GP6, P2RY6 P2RY12 18/4885TP53 4435/4885MAPT 4832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.